Tag
Zydus Lifesciences Limited
7 articles
Zydus Lifesciences concluded fiscal year 2026 on a strong note, demonstrating a 16% year-over-year revenue increase driven by robust performance in its India branded formulations business and new product launches in North America. The company is returning value to shareholders through an ₹11,000 million share buyback and has further strengthened its leadership team with the reappointment of Dr. Sharvil P. Patel as Managing Director and the addition of Kulin S. Lalbhai as an Independent Director. Strategic acquisitions, including US-based Assertio Holdings, alongside biosimilar launches like Tishtha and Anyra, signal Zydus’s commitment to expanding its global footprint and diversifying its product portfolio, positioning the company for continued growth despite ongoing regulatory scrutiny at a biologics facility.
Zydus Lifesciences Completes Torrent Urja 25 Investment
Zydus Lifesciences and subsidiaries invested Rs 90.18 million in Torrent Urja 25 equity shares on May 19, 2026.
The investment completes the four-tranche subscription totaling Rs 128.83 million for a
Zydus Lifesciences Promoters Intend to Participate in Buyback
Zydus Lifesciences intimates exchanges of its promoters' intention to participate in the company's ongoing share buyback.
The buyback is for up to 95.65 lakh shares (0.95% equity) at ₹1,150 per share,
Zydus Lifesciences Q4 Revenue Up 16% YoY, Announces Dividend and Buyback
Zydus Lifesciences reported Q4 FY26 revenue growth of 16.2% YoY to ₹75.87 billion and EBITDA growth of 20.2% to ₹25.54 billion.
The Board recommended a 100% dividend for FY26 and approved a share buyb
Zydus Lifesciences Q4 Revenue Up 16% YoY
Zydus Lifesciences reported Q4 FY26 revenue of ₹75,870 mn, a 16% YoY growth, with EBITDA margin expanding 110 bps to 33.7%.
The India branded formulations business grew 15% YoY, outperforming the mark
Zydus Lifesciences Reappoints MD, Appoints Independent Director
Zydus Lifesciences Board approves reappointment of Dr. Sharvil P. Patel as Managing Director for 5 years effective April 1, 2027.
Board appoints Mr. Kulin S. Lalbhai as Additional and Independent Dire
Zydus Lifesciences Approves ₹1,100 Crore Share Buyback
Zydus Lifesciences board approved a ₹1,100 crore share buyback of up to 0.95% equity at ₹1,150 per share via tender offer.
The buyback size represents 5.16% and 3.84% of standalone and consolidated ne
Zydus Lifesciences Q4 Net Profit ₹12.7B, Recommends Dividend
• Board approved audited FY26 results with unmodified audit opinion from Deloitte Haskins & Sells LLP.
• Recommended a final dividend of ₹1 per share (100%) subject to shareholder approval at the AGM